scholarly journals HLA-A2-restricted Cytotoxic T Lymphocyte Epitopes from Human Hepsin as Novel Targets for Prostate Cancer Immunotherapy

2013 ◽  
Vol 78 (3) ◽  
pp. 248-257 ◽  
Author(s):  
J. Guo ◽  
G. Li ◽  
J. Tang ◽  
X.-B. Cao ◽  
Q.-Y. Zhou ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Immunotherapy ◽  
T Lymphocyte ◽  
Cytotoxic T Lymphocyte ◽  
Novel Targets

Photosensitizer-induced self-assembly of antigens as nanovaccines for cancer immunotherapy

2018 ◽  
Vol 6 (3) ◽  
pp. 473-477 ◽  
Author(s):  
F. Q. Cao ◽  
M. M. Yan ◽  
Y. J. Liu ◽  
L. X. Liu ◽  
L. Lu ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Laser Irradiation ◽  
T Lymphocyte ◽  
Self Assembly ◽  
Near Infrared ◽  
Cytotoxic T Lymphocyte ◽  
Lymphocyte Response ◽  
Cross Presentation ◽  
Cytotoxic T Lymphocyte Response ◽  
Nir Laser

Under near-infrared (NIR) laser irradiation, ICG–antigen conjugate-based nanovaccines enhanced the cross-presentation of antigens and induced cytotoxic T lymphocyte response.

scholarly journals Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

2014 ◽  
Vol 211 (4) ◽  
pp. 715-725 ◽  
Author(s):  
Xiaozhou Fan ◽  
Sergio A. Quezada ◽  
Manuel A. Sepulveda ◽  
Padmanee Sharma ◽  
James P. Allison
Keyword(s):  
Prostate Cancer ◽  
Monoclonal Antibody ◽  
Immune Responses ◽  
Tumor Cell ◽  
Cancer Patients ◽  
T Lymphocyte ◽  
Cytotoxic T Lymphocyte ◽  
Strong Support ◽  
Antitumor Effects ◽  
Tumor Cell Vaccines

Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade with a monoclonal antibody yields durable responses in a subset of cancer patients and has been approved by the FDA as a standard therapy for late-stage melanoma. We recently identified inducible co-stimulator (ICOS) as a crucial player in the antitumor effects of CTLA-4 blockade. We now show that concomitant CTLA-4 blockade and ICOS engagement by tumor cell vaccines engineered to express ICOS ligand enhanced antitumor immune responses in both quantity and quality and significantly improved rejection of established melanoma and prostate cancer in mice. This study provides strong support for the development of combinatorial therapies incorporating anti–CTLA-4 and ICOS engagement.

scholarly journals Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy

2021 ◽  
Vol 12 ◽  
Author(s):  
Muhammad Khan ◽  
Sumbal Arooj ◽  
Hua Wang
Keyword(s):  
Cancer Immunotherapy ◽  
T Lymphocyte ◽  
Cytotoxic T Lymphocyte ◽  
Chronic Infections ◽  
Tumor Immune Evasion ◽  
Checkpoint Proteins ◽  
Cell Responses ◽  
Anti Cancer ◽  
Immune Checkpoint Proteins ◽  
Proteolytic Shedding

Co-inhibitory B7-CD28 family member proteins negatively regulate T cell responses and are extensively involved in tumor immune evasion. Blockade of classical CTLA-4 (cytotoxic T lymphocyte-associated antigen-4) and PD-1 (programmed cell death protein-1) checkpoint pathways have become the cornerstone of anti-cancer immunotherapy. New inhibitory checkpoint proteins such as B7-H3, B7-H4, and BTLA (B and T lymphocyte attenuator) are being discovered and investigated for their potential in anti-cancer immunotherapy. In addition, soluble forms of these molecules also exist in sera of healthy individuals and elevated levels are found in chronic infections, autoimmune diseases, and cancers. Soluble forms are generated by proteolytic shedding or alternative splicing. Elevated circulating levels of these inhibitory soluble checkpoint molecules in cancer have been correlated with advance stage, metastatic status, and prognosis which underscore their broader involvement in immune regulation. In addition to their potential as biomarker, understanding their mechanism of production, biological activity, and pathological interactions may also pave the way for their clinical use as a therapeutic target. Here we review these aspects of soluble checkpoint molecules and elucidate on their potential for anti-cancer immunotherapy.

scholarly journals HLA-A2–Restricted Cytotoxic T Lymphocyte Epitopes from Human Heparanase as Novel Targets for Broad-Spectrum Tumor Immunotherapy

Neoplasia ◽  
2008 ◽  
Vol 10 (9) ◽  
pp. 977-986 ◽  
Author(s):  
Ting Chen ◽  
Xu-Dong Tang ◽  
Yin Wan ◽  
Ling Chen ◽  
Song-Tao Yu ◽  
...  
Keyword(s):  
T Lymphocyte ◽  
Broad Spectrum ◽  
Cytotoxic T Lymphocyte ◽  
Tumor Immunotherapy ◽  
Novel Targets

Broadly expressed tumour?associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy

2005 ◽  
Vol 5 (9) ◽  
pp. 1183-1192 ◽  
Author(s):  
Gavin M Bendle ◽  
Angelika Holler ◽  
Anne-Marie Downs ◽  
Shao-An Xue ◽  
Hans J Stauss
Keyword(s):  
Cancer Immunotherapy ◽  
T Lymphocyte ◽  
Cytotoxic T Lymphocyte ◽  
Associated Proteins
Sign in / Sign up

Export Citation Format

Share Document